
New York/R&D/Ctr/Translational Med/Ther Profile last edited on: 9/6/2023
CAGE: 6XU64
UEI: JBDNWL5M9D43
Business Identifier: NO Business Identifier is currently available for this company. Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 17
County: Westchester
Congr. District: 17
County: Westchester
Public Profile
Founded by Dr. Herb Sun, former Director of Orthopaedic Research and Professor of Orthopaedic Surgery at Albert Einstein College of Medicine, New York R&D Center for Translational Medicine and Therapeutics (NY.TmT) is an R&D company pursuing commercialization of therapies addressing musculoskeletal diseases and disorders, such as tendinopathy and osteoarthritis. In particular, foxus is on tendinopathy - a painful, chronic disease of the tendon with degeneration of the tissue and cellular structures, which often leads to tendon rupture. Current development of miR-T1, a novel microRNA-based therapeutic, that aims to provide a disease-modifying therapy for tendinopathy by restoring tendon function and alleviating pain.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 2 | NIH | $766,270 | |
Project Title: Exosome drug for tendinopathy | ||||
2023 | 2 | NIH | $1,866,402 | |
Project Title: miRNA drug for tendinopathy | ||||
2021 | 2 | NIH | $2,001,279 | |
Project Title: A Novel Product for Tendinopathy Treatment | ||||
2018 | 1 | NIH | $225,000 | |
Project Title: A Novel Nutraceutical Drug for Tendinopathy Treatment | ||||
2018 | 1 | NIH | $225,392 | |
Project Title: Gene and Stem Cell-Based Treatment for Tendinopathy |
Key People / Management
Hui B Sun -- Founder, CEO and President
David T Fung -- Chief R&D Officer
Daniel J Leong -- Chief Strategy Officer
Li Sun -- VP, Research
David T Fung -- Chief R&D Officer
Daniel J Leong -- Chief Strategy Officer
Li Sun -- VP, Research
Company News
There are no news available.